- Home
- SXTC vs MEIP Comparison
SXTC vs MEIP Comparison
Compare SXTC & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTC
- MEIP
- Stock Information
- Founded
- SXTC 2005
- MEIP 2000
- Country
- SXTC China
- MEIP United States
- Employees
- SXTC 75
- MEIP N/A
- Industry
- SXTC Biotechnology: Pharmaceutical Preparations
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- SXTC Health Care
- MEIP Health Care
- Exchange
- SXTC Nasdaq
- MEIP Nasdaq
- Market Cap
- SXTC 186.8M
- MEIP 153.9M
- IPO Year
- SXTC 2019
- MEIP 2003
- Fundamental
- Price
- SXTC $1.60
- MEIP $4.91
- Analyst Decision
- SXTC
- MEIP
- Analyst Count
- SXTC 0
- MEIP 0
- Target Price
- SXTC N/A
- MEIP N/A
- AVG Volume (30 Days)
- SXTC 72.8K
- MEIP 3.2M
- Earning Date
- SXTC 01-01-0001
- MEIP 09-18-2025
- Dividend Yield
- SXTC N/A
- MEIP N/A
- EPS Growth
- SXTC N/A
- MEIP N/A
- EPS
- SXTC N/A
- MEIP N/A
- Revenue
- SXTC $1,740,907.00
- MEIP N/A
- Revenue This Year
- SXTC N/A
- MEIP N/A
- Revenue Next Year
- SXTC N/A
- MEIP N/A
- P/E Ratio
- SXTC N/A
- MEIP N/A
- Revenue Growth
- SXTC N/A
- MEIP 33.76
- 52 Week Low
- SXTC $0.95
- MEIP $1.46
- 52 Week High
- SXTC $8.64
- MEIP $9.00
- Technical
- Relative Strength Index (RSI)
- SXTC 48.05
- MEIP 53.94
- Support Level
- SXTC $1.50
- MEIP $4.62
- Resistance Level
- SXTC $1.66
- MEIP $5.19
- Average True Range (ATR)
- SXTC 0.10
- MEIP 0.46
- MACD
- SXTC 0.01
- MEIP -0.16
- Stochastic Oscillator
- SXTC 45.83
- MEIP 15.93
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.